A Phase I Study Evaluating the Multiple-Dose Safety, Tolerability, and Pharmacokinetics of an Intravenous Beta-Lactamase Inhibitor in Healthy Young Male Volunteers
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Cilastatin/imipenem/relebactam (Primary)
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 18 Jun 2018 Results of pooled data from two phase1 trial, were published in the Antimicrobial Agents and Chemotherapy.
- 17 Sep 2012 New trial record